We report the inhibitory effect of 4-methylesculetin (ME), a 4methylumbelliferone derivative, on hyaluronan (HA) synthesis by pancreatic cancer cells, and its resulting anticancer action. First, HA in cell culture was analyzed using competitive inhibition with hyaluronic acid-binding protein (HABP)
Effect of dibutyryl cyclic AMP on the cell cycle of human pancreatic cancer inoculated in nude mice
✍ Scribed by A. Umezawa; K. Koyama; J. Tanaka; Y. Sato; Y. Asanuma
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 408 KB
- Volume
- 58
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The prognosis of pancreatic cancer is very poor because of its high malignant potential. To improve the prognosis of pancreatic cancer, a decrease in the grade of maligancy by dibutyryl cyclic AMP (db‐cAMP), a differentiation inducer, was attempted using human pancreatic cancer cell line inoculated to nude mice.
In this study, 0.1 or 5.0 μmol/animal/day of db‐cAMP was administered for 7 consecutive days in short‐term group animals and for 28 consecutive days in long‐term group animals. Animals in both groups are sacrificed 28 days after first administration of db‐cAMP, and tumor size, histology, and cell cycle analysis using flow cytometry (FCM) were studied.
Tumor size and histology showed no significant changes by db‐cAMP. However, in cell cycle analysis, 5.0 μmol/animal/day of db‐cAMP brought significant block of the cell cycle phases between G1 and S in the short‐term group and the phase between S and G2/M in the long‐term group, indicating a decrease in cell cycle speed and, consequently, a decrease in the proliferation of tumor cell.
The results show that db‐cAMP may be useful in decreasing the grade of malignancy of pancreatic cancer. © 1995 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Experiments have been performed to clarify whether LHRH agonists might decrease growth of hormone-unresponsive prostate cancer in vivo. Male nude mice were injected s.c. with the human androgen-independent prostate tumor DU 145 cells; osmotic minipumps releasing the LHRH agonist Zoladex (LHRH-A) for
The antiproliferative effect of the new antiestrogen EM-800 has been studied during 40 weeks of treatment on human breast carcinoma ZR-75-1 xenografts in ovariectomized nude mice supplemented with estrone (0.5 g, s.c. daily). At the daily 50 g (approximately 2.5 mg/kg) oral dose, EM-800 caused a com
The effects of the novel anti-estrogen EM-343 on the growth of 2 hormone-responsive human breast cancer tumors have been examined in athymic nude mice. At the low daily dose of 5 g, EM-343 administered subcutaneously for 6 months completely blocked the stimulatory effect of endogenous estrogens on t
We have examined the anti-tumor effect in nude mice caused by human pancreatic cancer cells (AsPC-1) modified to secrete IL-2 or IL-4. Loss of tumorigenicity of cytokineproducing, but not wild-type, cells was observed despite their unaltered in vitro proliferation rates; and these anti-tumor effects